ABEC lance la plateforme ATB™-2100 pour transformer la fabrication des thérapies de pointe

The Quick Take
BETHLEHEM, Pennsylvanie, 6 novembre 2026 /PRNewswire/ -- ABEC, un leader mondial des solutions et services d'ingénierie pour la fabrication biopharmaceutique, annonce aujourd'hui le lancement commercial du bioréacteur de thérapie de pointe ATB™-2100, une technologie révolutionnaire...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alphabet Inc. of Class Action Lawsuit and Upcoming Deadlines - GOOG
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alphabet Inc. ("Alphabet" or the "Company")…
Business
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ethos Technologies Inc. - LIFE
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ethos Technologies Inc. ("Ethos" or the "Company")…
Business
Phase II Study of Ivonescimab in the Perioperative Setting for Resectable NSCLC Published in Nature Medicine
HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that results from a Phase II clinical study evaluating its first-in-class…
Business
MNTN Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into MNTN, Inc. (MNTN)
MNTN reported third-quarter 2026 adjusted earnings of $0.10 per share, missing the $0.25 consensus, and cut its full-year revenue outlook due to sales…
